[go: up one dir, main page]

MA50817B1 - Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide - Google Patents

Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Info

Publication number
MA50817B1
MA50817B1 MA50817A MA50817A MA50817B1 MA 50817 B1 MA50817 B1 MA 50817B1 MA 50817 A MA50817 A MA 50817A MA 50817 A MA50817 A MA 50817A MA 50817 B1 MA50817 B1 MA 50817B1
Authority
MA
Morocco
Prior art keywords
ynoyl
pyrazin
imidazo
pyrrolidin
pyridin
Prior art date
Application number
MA50817A
Other languages
English (en)
Other versions
MA50817A (fr
Inventor
Jerry Evarts
Tjeerd Barf
Fritz Blatter
Tim Ingallinera
Edwin Aret
Cecile Krejsa
Original Assignee
Acerta Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56363881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50817(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv
Publication of MA50817A publication Critical patent/MA50817A/fr
Publication of MA50817B1 publication Critical patent/MA50817B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)

Abstract

La présente demande concerne des formes cristallines de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl )-n-(pyridin-2-yl)benzamide base libre et aux formes cristallines de ses sels, compositions de celles-ci et utilisations en médecine.
MA50817A 2015-07-02 2016-07-01 Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide MA50817B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562188468P 2015-07-02 2015-07-02
US201562271708P 2015-12-28 2015-12-28

Publications (2)

Publication Number Publication Date
MA50817A MA50817A (fr) 2021-04-21
MA50817B1 true MA50817B1 (fr) 2021-10-29

Family

ID=56363881

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50817A MA50817B1 (fr) 2015-07-02 2016-07-01 Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Country Status (29)

Country Link
US (7) US9796721B2 (fr)
EP (4) EP3954690B1 (fr)
JP (3) JP6829215B2 (fr)
KR (2) KR102688052B1 (fr)
CN (2) CN108349978B (fr)
AU (3) AU2016286548B2 (fr)
CA (1) CA2991096A1 (fr)
CL (1) CL2017003445A1 (fr)
CY (3) CY1124519T1 (fr)
DK (3) DK3954690T3 (fr)
ES (3) ES2895802T3 (fr)
FI (1) FI3954690T3 (fr)
HR (3) HRP20211511T1 (fr)
HU (3) HUE056008T2 (fr)
IL (3) IL274066B (fr)
LT (3) LT3317281T (fr)
MA (1) MA50817B1 (fr)
MD (1) MD3317281T2 (fr)
MX (2) MX378495B (fr)
MY (1) MY193514A (fr)
PL (3) PL3613745T3 (fr)
PT (3) PT3613745T (fr)
RS (3) RS64195B1 (fr)
RU (1) RU2018103913A (fr)
SG (1) SG10201913796UA (fr)
SI (3) SI3613745T1 (fr)
SM (3) SMT202300165T1 (fr)
WO (1) WO2017002095A1 (fr)
ZA (2) ZA201800329B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3179991T (lt) * 2014-08-11 2021-11-10 Acerta Pharma B.V. Terapiniai btk inhibitoriaus ir bcl-2 inhibitoriaus deriniai
HRP20211511T1 (hr) 2015-07-02 2021-12-24 Acerta Pharma B.V. Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida
PT3478286T (pt) 2016-06-29 2024-01-31 Tesaro Inc Métodos de tratamento do cancro do ovário
WO2018064797A1 (fr) 2016-10-05 2018-04-12 杭州领业医药科技有限公司 Forme cristalline d'acp-196, procédé de préparation et composition pharmaceutique associés
WO2018115965A1 (fr) * 2016-12-23 2018-06-28 Acerta Pharma Bv Formes solides de composés d'imidazopyrazine
US10899770B2 (en) 2017-02-20 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof
EP3606523A1 (fr) * 2017-03-27 2020-02-12 Tesaro, Inc. Formulations de niraparib
WO2018183354A1 (fr) 2017-03-27 2018-10-04 Tesaro, Inc. Compositions de niraparib
US10717740B2 (en) 2017-06-13 2020-07-21 Dr. Reddy's Laboratories Limited. Solid forms of acalabrutinib and process for preparation thereof
US11345706B2 (en) 2017-08-29 2022-05-31 Apotex Inc. Crystalline forms of Acalabrutinib
EP3687505A1 (fr) 2017-09-26 2020-08-05 Tesaro Inc. Formulations de niraparib
WO2019105359A1 (fr) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Forme cristalline de l'acalabrutinib, son procédé de préparation et son application
US11091494B2 (en) 2018-01-05 2021-08-17 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of acalabrutinib and preparation method and use thereof
WO2019159097A1 (fr) * 2018-02-14 2019-08-22 Sun Pharmaceutical Industries Limited Nouvelles formes polymorphes cristallines d'acalabrutinib
WO2019205812A1 (fr) * 2018-04-26 2019-10-31 苏州科睿思制药有限公司 Nouvelle forme cristalline de l'acalabrutinib, son procédé de préparation et son utilisation
EP3587421A1 (fr) 2018-06-29 2020-01-01 Sandoz AG Formes cristallines de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo [1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
CN112638878B (zh) 2018-08-29 2025-07-22 安塞塔制药公司 制备阿卡拉布替尼的方法
WO2020053795A2 (fr) 2018-09-13 2020-03-19 Fresenius Kabi Oncology Ltd. Procédé de préparation d'acalabrutinib et de ses intermédiaires
EP3830091A1 (fr) * 2018-09-25 2021-06-09 Cipla Limited Nouveaux polymorphes d'acalabrutinib, un inhibiteur de la tyrosine kinase de bruton
US20220153744A1 (en) 2019-03-27 2022-05-19 Assia Chemical Industries Ltd. Solid state forms of acalabrutinib
WO2020225831A1 (fr) * 2019-05-09 2020-11-12 Msn Laboratories Private Limited, R&D Center Procédé amélioré pour la préparation de 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
WO2021135346A1 (fr) * 2019-12-31 2021-07-08 苏州科睿思制药有限公司 Nouvelle forme cristalline de l'acalabrutinib, son procédé de préparation et son utilisation
WO2021239893A1 (fr) 2020-05-29 2021-12-02 Bend Research, Inc. Dispersion solide amorphe d'acalabrutinib
CR20230018A (es) * 2020-06-19 2023-04-11 Acerta Pharma Bv Formas farmacéuticas de maleato de acalabrutinib
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法
US20240315978A1 (en) * 2021-01-13 2024-09-26 Natco Pharma Limited Pharmaceutical compositions comprising acalabrutinib
WO2023014817A1 (fr) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions et méthodes pour traiter des lymphomes avec un inhibiteur de cdk7 en combinaison avec un inhibiteur de btk
WO2023205279A1 (fr) * 2022-04-19 2023-10-26 The Johns Hopkins University Spectroscopie raman améliorée avec addition de composés aromatiques
EP4662214A1 (fr) * 2023-02-09 2025-12-17 Apotex Inc. Formes cristallines de maléate d'acalabrutinib
WO2025125383A1 (fr) 2023-12-11 2025-06-19 Synthon B.V. Formes cristallines d'hydrogénomaléate d'acalabrutinib

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
CN1390220A (zh) 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的激酶抑制剂
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
BRPI0415395A (pt) 2003-10-15 2006-12-12 Osi Pharm Inc composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
AR048518A1 (es) 2004-04-02 2006-05-03 Osi Pharm Inc Inhibidores heterobiciclicos de proteina quinasas sustituidos con anillos 6,6 -biciclicos
ITMI20051231A1 (it) 2005-06-29 2006-12-30 Pharmaproducts Uk Ltd Formulazioni farmaceutiche contenenti colostro e calcio folinato per il trattamento delle affezioni del cavo orale
CN101252932B (zh) 2005-09-09 2012-10-03 安吉利尼莱博法姆有限责任公司 用于一天给药一次的曲唑酮组合物
CA2630271C (fr) 2005-11-17 2014-04-08 Osi Pharmaceuticals, Inc. Inhibiteurs mtor bicycliques condenses
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
EP1996193A2 (fr) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Traitement combiné avec un inhibiteur de kinase egfr et un agent sensibilisant les cellules tumorales aux effets des inhibiteurs de kinase egfr
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
EA017865B1 (ru) 2007-03-28 2013-03-29 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
JP2011506455A (ja) 2007-12-13 2011-03-03 ノバルティス アーゲー 癌を処置するための治療薬の組み合わせ剤
US9095592B2 (en) 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2424368B1 (fr) 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Composés de pyrrolotriazine
CA2787291C (fr) 2010-02-08 2016-04-19 Msd Oss B.V. Composes de 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
MY169745A (en) 2010-05-31 2019-05-14 Ono Pharmaceutical Co Purinone derivative
EA201890869A3 (ru) 2010-06-03 2019-03-29 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk)
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
ES2770550T3 (es) 2011-05-17 2020-07-02 Univ California Inhibidores de quinasa
AU2012275275A1 (en) 2011-06-28 2014-01-23 Pharmacyclics Llc Methods and compositions for inhibition of bone resorption
AU2012283775A1 (en) 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
JP5826931B2 (ja) * 2011-07-19 2015-12-02 メルク・シャープ・エンド・ドーム・ベー・フェー Ｂｔｋ阻害剤としての４−イミダゾピリダジン−１−イル−ベンズアミドおよび４−イミダゾトリアジン−１−イル−ベンズアミド
EP2548877A1 (fr) 2011-07-19 2013-01-23 MSD Oss B.V. Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
WO2013010869A1 (fr) 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides inhibiteurs de btk
KR102054468B1 (ko) 2011-10-19 2019-12-11 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(btk)의 억제제의 용도
US20140212425A1 (en) 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
MX355409B (es) * 2012-05-23 2018-04-18 Nerviano Medical Sciences Srl Proceso para la preparacion de n- [5- (3,5-difluoro-bencil) -1h-indazol-3-il] -4- (4-metil-piperazin-1-il) -2- (tetrahidro-piran-4-ilamino) -benzamida.
US20140206681A1 (en) 2013-01-23 2014-07-24 Ronald M. Kim Btk inhibitors
US20160022683A1 (en) 2013-03-14 2016-01-28 Pharmacyclics Llc Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
WO2014143807A2 (fr) 2013-03-15 2014-09-18 Stromatt Scott Anticorps anti-cd37 et polythérapie par antagoniste de la voie bcr pour le traitement de malignités b et de troubles des lymphocytes b
BR112015025711A8 (pt) 2013-04-08 2019-12-17 Janssen Pharmaceutica Nv uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer
US9999623B2 (en) 2013-04-08 2018-06-19 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
WO2015018522A1 (fr) 2013-08-06 2015-02-12 Oncoethix Sa Inhibiteur de bromodomaine bet présentant une synergie avec plusieurs agents anti-cancéreux dans des modèles cliniques de lymphome diffus de cellule b de grande taille (dlbcl)
WO2015057992A1 (fr) 2013-10-16 2015-04-23 Izumi Raquel Inhibiteurs btk pour la mobilisation hématopoïétique
US10328080B2 (en) 2013-12-05 2019-06-25 Acerta Pharma, B.V. Therapeutic combination of PI3K inhibitor and a BTK inhibitor
JP6219523B2 (ja) 2013-12-13 2017-10-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼの阻害剤
WO2015110923A2 (fr) 2014-01-21 2015-07-30 Acerta Pharma B.V. Méthodes de traitement de la leucémie lymphoïde chronique et du lymphome à petits lymphocytes en utilisant un inhibiteur de btk
FR3021783B1 (fr) 2014-06-02 2016-05-13 Morpho Procede de validation de l'authenticite d'un element du corps humain
HRP20211511T1 (hr) * 2015-07-02 2021-12-24 Acerta Pharma B.V. Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida

Also Published As

Publication number Publication date
HUE049989T2 (hu) 2020-11-30
CY1126103T1 (el) 2023-11-15
PL3954690T3 (pl) 2023-08-14
KR20240115937A (ko) 2024-07-26
MY193514A (en) 2022-10-17
CN113480542B (zh) 2025-07-25
EP3954690B1 (fr) 2023-04-05
PT3613745T (pt) 2021-10-14
RU2018103913A (ru) 2019-08-02
EP4209493A1 (fr) 2023-07-12
AU2022291635A1 (en) 2023-02-02
LT3613745T (lt) 2021-10-11
US11820777B2 (en) 2023-11-21
PT3954690T (pt) 2023-06-06
IL293821A (en) 2022-08-01
US10167291B2 (en) 2019-01-01
MD3317281T2 (ro) 2020-07-31
EP3317281B1 (fr) 2020-04-22
US20240199622A1 (en) 2024-06-20
US20220177476A1 (en) 2022-06-09
LT3317281T (lt) 2020-07-27
RS60411B1 (sr) 2020-07-31
RU2018103913A3 (fr) 2019-12-31
MX378495B (es) 2025-03-11
HUE056008T2 (hu) 2022-01-28
SMT202000304T1 (it) 2020-07-08
PL3317281T3 (pl) 2020-11-02
JP2018522877A (ja) 2018-08-16
SMT202100597T1 (it) 2021-11-12
EP3613745B1 (fr) 2021-09-01
CN108349978A (zh) 2018-07-31
DK3317281T3 (da) 2020-06-15
AU2022291635B2 (en) 2024-06-27
CN108349978B (zh) 2021-07-23
CL2017003445A1 (es) 2018-05-11
AU2020277123A1 (en) 2020-12-24
US11059829B2 (en) 2021-07-13
MA50817A (fr) 2021-04-21
US10640509B2 (en) 2020-05-05
WO2017002095A1 (fr) 2017-01-05
SI3954690T1 (sl) 2023-07-31
EP3317281A1 (fr) 2018-05-09
US20190337949A1 (en) 2019-11-07
SG10201913796UA (en) 2020-03-30
PL3613745T3 (pl) 2022-01-31
JP2022120156A (ja) 2022-08-17
CN113480542A (zh) 2021-10-08
CY1124815T1 (el) 2022-11-25
KR20180048593A (ko) 2018-05-10
IL274066A (en) 2020-06-30
IL274066B (en) 2022-07-01
SMT202300165T1 (it) 2023-07-20
HK1250511A1 (en) 2018-12-21
ES2946489T3 (es) 2023-07-19
DK3954690T3 (da) 2023-06-06
ES2797987T3 (es) 2020-12-04
PT3317281T (pt) 2020-06-18
HRP20200934T1 (hr) 2020-09-18
JP2021073235A (ja) 2021-05-13
US20180208596A1 (en) 2018-07-26
SI3317281T1 (sl) 2020-08-31
US20220348582A1 (en) 2022-11-03
MX2018000179A (es) 2018-06-27
JP7091494B2 (ja) 2022-06-27
EP3613745A1 (fr) 2020-02-26
LT3954690T (lt) 2023-05-25
KR102688052B1 (ko) 2024-07-25
RS62455B1 (sr) 2021-11-30
DK3613745T3 (da) 2021-10-18
US20170029428A1 (en) 2017-02-02
CY1124519T1 (el) 2022-03-24
AU2020277123B2 (en) 2022-09-29
HUE062258T2 (hu) 2023-10-28
FI3954690T3 (fi) 2023-05-31
HRP20211511T1 (hr) 2021-12-24
ZA201800329B (en) 2022-04-28
RS64195B1 (sr) 2023-06-30
JP6829215B2 (ja) 2021-02-10
MX2020014163A (es) 2022-09-29
EP4209493B1 (fr) 2025-11-12
US20200255437A1 (en) 2020-08-13
US9796721B2 (en) 2017-10-24
SI3613745T1 (sl) 2021-12-31
EP3954690A1 (fr) 2022-02-16
ES2895802T3 (es) 2022-02-22
CA2991096A1 (fr) 2017-01-05
AU2016286548B2 (en) 2020-12-10
ZA202000300B (en) 2022-03-30
IL256633B (en) 2020-05-31
IL256633A (en) 2018-02-28
AU2016286548A1 (en) 2018-02-01
HRP20230417T1 (hr) 2023-07-07

Similar Documents

Publication Publication Date Title
MA50817B1 (fr) Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
MX2016000646A (es) Sulfonamidas como moduladores de canales de sodio.
MX368833B (es) Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor.
EA201590748A1 (ru) Противовирусные соединения против rsv
NZ750187A (en) Pyridone amides as modulators of sodium channels
CR20170263A (es) Forma cristalina de sulfato acido de (s)-n- (5- ( (r)-2- (2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]-pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
EA201591379A1 (ru) Липопротеин-ассоциированные ингибиторы фосфолипазы a2 (lp-pla) на основе 2,3-дигидроимидазо[1,2-с]пиримидин-5(1h)-онов
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
EA201792558A1 (ru) Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль
TR201309037A2 (tr) Dapoksetin ve bir pde5 inhibitörü içeren yeni efervesan saşe formülasyonları.
MA57556B1 (fr) Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
MA57504B1 (fr) Forme cristalline d'hydrogénosulfate de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide